BioCryst Pharmaceuticals

BioCryst Pharmaceuticals BCRX Stock

$7.32   0.273972%
Add to favorites
Market Cap
$1.88B
LOW - HIGH [24H]
$7.20 - $7.39
VOLUME [24H]
$3.78M
P/E Ratio
0
Earnings per share
-$1.28
ISIN
US09058V1035
Price   Prediction

BioCryst Pharmaceuticals Price Chart

Sorry, that's all we've gotfor now...

BioCryst Pharmaceuticals (BCRX) stock price today is 7.32 USD on Tech Market Large (+0.27% on the day). Updated .

BioCryst Pharmaceuticals BCRX Financial and Trading Overview

BioCryst Pharmaceuticals stock price 7.32 USD
Previous Close 7.45 USD
Open 7.4 USD
Bid 7.5 USD x 100
Ask 8.48 USD x 100
Day's Range 7.33 - 7.52 USD
52 Week Range 6.23 - 11.22 USD
Volume 3.88M USD
Avg. Volume 4.93M USD
Market Cap 1.93B USD
Beta (5Y Monthly) 0.513
PE Ratio (TTM) N/A
EPS (TTM) -1.28 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 20.45 USD

BCRX Valuation Measures

Enterprise Value 2.38B USD
Trailing P/E N/A
Forward P/E 8.77193
PEG Ratio (5 yr expected) 9.39
Price/Sales (ttm) 2.0069938
Price/Book (mrq) N/A
Enterprise Value/Revenue 2.478
Enterprise Value/EBITDA 5.044

Trading Information

BioCryst Pharmaceuticals Stock Price History

Beta (5Y Monthly) 0.513
52-Week Change 8.22%
S&P500 52-Week Change 10.51%
52 Week High 11.22 USD
52 Week Low 6.23 USD
50-Day Moving Average 8.15 USD
200-Day Moving Average 8.81 USD

BCRX Share Statistics

Avg. Volume (3 month) 4.93M USD
Avg. Daily Volume (10-Days) 5.69M USD
Shares Outstanding 257.3M
Float 224.08M
Short Ratio 5.11
% Held by Insiders 1.26%
% Held by Institutions 95.08%
Shares Short 27.64M
Short % of Float 10.82%
Short % of Shares Outstanding 10.74%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin -37.40%
Operating Margin (ttm) 48.75%
Gross Margin 78.12%
EBITDA Margin 49.13%

Management Effectiveness

Return on Assets (ttm) 56.47%
Return on Equity (ttm) N/A

Income Statement

Revenue (ttm) 961.51M USD
Revenue Per Share (ttm) 3.99 USD
Quarterly Revenue Growth (yoy) 13.10%
Gross Profit (ttm) 751.18M USD
EBITDA 472.47M USD
Net Income Avi to Common (ttm) -359656000 USD
Diluted EPS (ttm) -1.28
Quarterly Earnings Growth (yoy) 193.90%

Balance Sheet

Total Cash (mrq) 375M USD
Total Cash Per Share (mrq) 1.46 USD
Total Debt (mrq) 828.2M USD
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 2.712
Book Value Per Share (mrq) -1.552

Cash Flow Statement

Operating Cash Flow (ttm) 367.49M USD
Levered Free Cash Flow (ttm) 301.09M USD

Profile of BioCryst Pharmaceuticals

Country United States
State NC
City Durham
Address 4505 Emperor Boulevard
ZIP 27703
Phone 919 859 1302
Website https://www.biocryst.com
Industry Drug Manufacturers - Specialty & Generic
Sector(s) Healthcare
Full Time Employees 435

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Q&A For BioCryst Pharmaceuticals Stock

What is a current BCRX stock price?

BioCryst Pharmaceuticals BCRX stock price today per share is 7.32 USD.

How to purchase BioCryst Pharmaceuticals stock?

You can buy BCRX shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for BioCryst Pharmaceuticals?

The stock symbol or ticker of BioCryst Pharmaceuticals is BCRX.

Which industry does the BioCryst Pharmaceuticals company belong to?

The BioCryst Pharmaceuticals industry is Drug Manufacturers - Specialty & Generic.

How many shares does BioCryst Pharmaceuticals have in circulation?

The max supply of BioCryst Pharmaceuticals shares is 257.3M.

What is BioCryst Pharmaceuticals Price to Earnings Ratio (PE Ratio)?

BioCryst Pharmaceuticals PE Ratio is now.

What was BioCryst Pharmaceuticals earnings per share over the trailing 12 months (TTM)?

BioCryst Pharmaceuticals EPS is -1.28 USD over the trailing 12 months.

Which sector does the BioCryst Pharmaceuticals company belong to?

The BioCryst Pharmaceuticals sector is Healthcare.

BioCryst Pharmaceuticals BCRX included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 23879.2 USD —
-2.25
8.33B USD — 23870.7 USD — 24939.62 USD — — 8.33B USD —
us US Tech Biotechnology Total Retu XNBI US 7541.29 USD —
-1.01
— — 7532.47 USD — 7685.86 USD — — — —
us US Tech US 700 Small Cap Index NQUS700SC US 2878.9 USD —
-2.1
— — 2877.85 USD — 2954.75 USD — — — —
us US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG US 3557.41 USD —
-2.29
— — 3555.54 USD — 3690.74 USD — — — —
us US Tech Biotechnology NBI US 6901.37 USD —
-1.01
— — 6893.3 USD — 7033.67 USD — — — —
us US Tech Health Care IXHC US 1306.01 USD —
-1.39
— — 1303.72 USD — 1333.62 USD — — — —
us US Tech Composite Total Return XCMP US 29515.56 USD —
-2.24
— — 29505.06 USD — 30826.03 USD — — — —
us US Tech Global Select Market Com NQGS US 11763.07 USD —
-2.26
— — 11758.76 USD — 12288.24 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
$2.14T
Total marketcap
$75.42B
Total volume
BTC 57.88%   •   ETH 9.95%
Dominance
Select currency